Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 4, 2013, Pages 427-435

  Krause, Bernd Joachim ^a   Souvatzoglou, Michael ^a   Treiber, Uwe ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

11C 18F choline; Imaging; PET; PET CT; Prostate cancer

Indexed keywords

3 METHYLGLUCOSE; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CAPROMAB PENDETIDE IN 111; CARBON 11; CHOLINE DERIVATIVE; DOCETAXEL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; TRACER;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; BONE METASTASIS; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; GLEASON SCORE; HUMAN; ISOTOPE LABELING; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDLINE; MICROMETASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY;

CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876724938     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.008     Document Type: Review

References (79)

1. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999, 36:31-35.
2. Nunez R., Macapinlac H.A., Yeung H.W., et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002, 43:46-55.
3. Morris M.J., Akhurst T., Osman I., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002, 59:913-918.
4. Albrecht S., Buchegger F., Soloviev D., et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007, 34:185-196.
5. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005, 32:344-350.
6. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000, 27:1415-1419.
7. Larson S.M., Morris M., Gunther I., et al. Tumor localization of 16beta-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45:366-373.
8. Toth G., Lengyel Z., Balkay L., et al. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005, 173:66-69. Discussion 9.
9. Wachter S., Tomek S., Kurtaran A., et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006, 24:2513-2519.
10. Ackerstaff E., Glunde K., Bhujwalla Z.M. Choline phospholipid metabolism: A target in cancer cells?. J Cell Biochem 2003, 90:525-533.
11. Casciani E., Gualdi G.F. Prostate cancer: Value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006, 31:490-499.
12. Ramirez de Molina A., Penalva V., Lucas L., et al. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002, 21:937-946.
13. Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296:580-583.
14. 3) spatial resolution. Radiology 1996, 198:795-805.
15. Kurhanewicz J., Vigneron D.B., Nelson S.J. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000, 2:166-189.
16. Ackerstaff E., Pflug B.R., Nelson J.B., et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001, 61:3599-3603.
17. Hara T., Bansal A., DeGrado T.R. choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006, 5:498-509.
18. Katz-Brull R., Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996, 16:1375-1380.
19. Ratnam S., Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995, 323:313-322.
20. Müller S.A., Holzapfel K., Seidl C., et al. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009, 36:1434-1442.
21. Haberkorn U., Bellemann M.E., Altmann A., et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 1997, 38:1215-1221.
22. Holzapfel K, Muller SA, Seidl C, et al. Effects of irradiation on the [methyl-3H]choline uptake in the human prostate cancer cell lines LNCaP and PC3. Strahlenther Onkol 184:319-24.
23. de Jong I.J., Pruim J., Elsinga P.H., et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002, 42:18-23.
24. Farsad M., Schiavina R., Castellucci P., et al. Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005, 46:1642-1649.
25. Giovacchini G., Picchio M., Coradeschi E., et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: Relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35:1065-1073.
26. Kwee S.A., Coel M.N., Lim J., et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005, 173:252-255.
27. Kwee S.A., Wei H., Sesterhenn I., et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006, 47:262-269.
28. Martorana G., Schiavina R., Corti B., et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006, 176:954-960. Discussion 60.
29. Reske S.N., Blumstein N.M., Neumaier B., et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006, 47:1249-1254.
30. Scher B., Seitz M., Albinger W., et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34:45-53.
31. Schmid D.T., John H., Zweifel R., et al. Fluorocholine PET/CT in patients with prostate cancer: Initial experience. Radiology 2005, 235:623-628.
32. Sutinen E., Nurmi M., Roivainen A., et al. Kinetics of [(11)C]choline uptake in prostate cancer: A PET study. Eur J Nucl Med Mol Imaging 2004, 31:317-324.
33. Yamaguchi T., Lee J., Uemura H., et al. Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005, 32:742-748.
34. Yoshida S., Nakagomi K., Goto S., et al. 11C-choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging. Urol Int 2005, 74:214-220.
35. de Jong I.J., Pruim J., Elsinga P.H., et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003, 44:331-335.
36. Schiavina R., Scattoni V., Castellucci P., et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: Comparison with clinical staging nomograms. Eur Urol 2008, 392-401.
37. Tuncel M., Souvatzoglou M., Herrmann K., et al. [(11)C]choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008, 35:689-695.
38. Freedland S.J., Presti J.C., Amling C.L., et al. Time trends in biochemical recurrence after radical prostatectomy: Results of the SEARCH database. Urology 2003, 61:736-741.
39. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523.
40. Chism D.B., Hanlon A.L., Horwitz E.M., et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:380-385.
41. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001, 76:576-581.
42. Bott S.R. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004, 7:211-216.
43. Connolly J.A., Shinohara K., Presti J.C., et al. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996, 47:225-231.
44. Shekarriz B., Upadhyay J., Wood D.P., et al. Vesico-urethral anastomosis biopsy after radical prostatectomy: Predictive value of prostate-specific antigen and pathologic stage. Urology 1999, 54:1044-1048.
45. Kramer S., Gorich J., Gottfried H.W., et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997, 70:995-999.
46. Coakley F.V., Teh H.S., Qayyum A., et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: Preliminary experience. Radiology 2004, 233:441-448.
47. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology 2004, 231:379-385.
48. Hoh C.K., Schiepers C., Seltzer M.A., et al. PET in oncology: Will it replace the other modalities?. Semin Nucl Med 1997, 27:94-106.
49. Jager G.J., Barentsz J.O., Oosterhof G.O., et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996, 167:1503-1507.
50. Oyen R.H., Van Poppel H.P., Ameye F.E., et al. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: Prospective study of 285 patients. Radiology 1994, 190:315-322.
51. Castellucci P., Fuccio C., Nanni C., et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009, 50:1394-1400.
52. de Jong I.J., Pruim J., Elsinga P.H., et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44:32-38. Discussion 8-9.
53. Heinisch M., Dirisamer A., Loidl W., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml?. Mol Imaging Biol 2006, 8:43-48.
54. Husarik D.B., Miralbell R., Dubs M., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
55. Krause B.J., Souvatzoglou M., Tuncel M., et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:18-23.
56. Picchio M., Messa C., Landoni C., et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003, 169:1337-1340.
57. Reske S.N., Blumstein N.M., Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008 Jan, 35:9-17.
58. Rinnab L., Mottaghy F.M., Blumstein N.M., et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007, 100:786-793.
59. Scattoni V., Picchio M., Suardi N., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52:423-429.
60. Cimitan M., Bortolus R., Morassut S., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398.
61. Kurdziel K., Bacharach S., Carrasquillo J., et al. Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin Positron Imaging 2000, 3:144.
62. Oyama N., Akino H., Suzuki Y., et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001, 22:963-969.
63. Coleman R., DeGrado T., Wang S., et al. Preliminary Evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000, 3:147.
64. Krause B.J., Souvatzoglou M., Herrmann K., et al. Monitoring of Docetaxel Therapy Response in a Mouse Prostate Xenograft Tumor Model by [11C]choline PET/CT. Eur J Nucl Med Mol Imaging 2008, 35:S218.
65. Contractor K.B., Aboagye E.O. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009, 50(Suppl 1):97S-105S.
66. Li X., Liu Q., Wang M., et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med 2008, 33:671-676.
67. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 2007, 99:1415-1420.
68. Pelosi E., Arena V., Skanjeti A., et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008, 113:895-904.
69. Steiner C., Vees H., Zaidi H., et al. 3-Phasen-PET/CT mit 18F-Fluor-Cholin zur Evaluation des Prostatakrebsrezidivs. Nuklearmedizin 2009, 48:1-9.
70. Ohlmann C., Pfister D., Thüer D., et al. 11C-choline-positron emission tomography/computerized tomographyY (11C-PET/CT) for tumor localization of locally recurrent prostate cancer after radiation therapy. Eur Urol 2007, 6(Suppl):229.
71. Breeuwsma A.J., Pruim J., van den Bergh A.C., et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010, 77:160-164.
72. Rinnab L., Mottaghy F.M., Simon J., et al. [11C]choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008, 81:191-197.
73. Rinnab L., Simon J., Hautmann R.E., et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009, 27:619-625.
74. Giovacchini G., Picchio M., Coradeschi E., et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-309.
75. Sodee D.B., Malguria N., Faulhaber P., et al. Multicenter ProstaScint imaging findings in 2,154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000, 56:988-993.
76. Jani A.B., Liauw S.L., Blend M.J. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res 2007, 5:123-131.
77. Kahn D., Williams R.D., Haseman M.K., et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998, 16:284-289.
78. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003, 21:1715-1721.
79. Nagda S.N., Mohideen N., Lo S.S., et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:834-840.